Eleni-Dimitra Papanagnou

发表

Isolation of an Extract from the Soft Coral Symbiotic Microorganism Salinispora arenicola Exerting Cytoprotective and Anti-Aging Effects

I. Trougakos, A. Sklirou, J. Ouazzani, 2021, Current issues in molecular biology.

Osirisynes G-I, New Long-Chain Highly Oxygenated Polyacetylenes from the Mayotte Marine Sponge Haliclona sp.

I. Trougakos, J. Bignon, G. Herbette, 2020, Marine drugs.

The Indirubin Derivative 6-Bromoindirubin-3′-Oxime Activates Proteostatic Modules, Reprograms Cellular Bioenergetic Pathways, and Exerts Antiaging Effects

J. Tchoumtchoua, I. Trougakos, A. Skaltsounis, 2017, Antioxidants & redox signaling.

Elucidating Carfilzomib’s Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of Metformin

M. Dimopoulos, I. Trougakos, I. Andreadou, 2021, International journal of molecular sciences.

Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report

M. Dimopoulos, A. Scorilas, T. Sphicopoulos, 2020, Life.

Cancer chemoprevention via activation of proteostatic modules.

I. Trougakos, A. Sklirou, N. Fokialakis, 2018, Cancer letters.

Autophagy activation can partially rescue proteasome dysfunction‐mediated cardiac toxicity

I. Trougakos, A. Sklirou, E. Kastritis, 2022, Aging cell.

The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment

M. Dimopoulos, I. Trougakos, E. Kastritis, 2021, Blood Cancer Journal.

Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis

M. Dimopoulos, I. Trougakos, A. Sklirou, 2021, HemaSphere.

Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose

M. Dimopoulos, I. Papassotiriou, I. Trougakos, 2021, Blood.

Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors

M. Dimopoulos, I. Trougakos, K. Koutsoukos, 2021, Journal of Hematology & Oncology.

Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events

L. Scorrano, I. Trougakos, A. Skaltsounis, 2017, Scientific Reports.

Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals

M. Dimopoulos, I. Papassotiriou, I. Trougakos, 2021, HemaSphere.

Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients

M. Dimopoulos, I. Papassotiriou, A. Scorilas, 2021, BMC Medicine.

Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study

M. Dimopoulos, I. Trougakos, E. Kastritis, 2021, Leukemia.

Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals

M. Dimopoulos, I. Trougakos, E. Kastritis, 2021, Life.

Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin.

M. Dimopoulos, I. Trougakos, I. Andreadou, 2019, Blood.

Age‐dependent and gender‐dependent antibody responses against SARS‐CoV‐2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine

M. Dimopoulos, I. Papassotiriou, I. Trougakos, 2021, American journal of hematology.

SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response

M. Dimopoulos, A. Scorilas, T. Sphicopoulos, 2021, Vaccines.

Nrf2 activation induces mitophagy and reverses Parkin/Pink1 knock down-mediated neuronal and muscle degeneration phenotypes

I. Trougakos, M. Manola, E. Papanagnou, 2021, Cell Death & Disease.

Micro-CT for Biological and Biomedical Studies: A Comparison of Imaging Techniques

Kleoniki Keklikoglou, Eva Chatzinikolaou, Christos Arvanitidis, 2021, J. Imaging.

Myeloma patients with COVID‐19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine

M. Dimopoulos, I. Trougakos, E. Kastritis, 2021, British journal of haematology.

Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy

M. Dimopoulos, I. Trougakos, E. Kastritis, 2022, Blood.

Comparison of neutralizing antibody responses against SARS‐CoV‐2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?

M. Dimopoulos, I. Trougakos, A. Sklirou, 2021, American journal of hematology.

Chios mastic improves blood pressure haemodynamics in patients with arterial hypertension: Implications for regulation of proteostatic pathways

I. Trougakos, I. Bakogianni, K. Karatzi, 2018, European journal of preventive cardiology.

Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events

L. Scorrano, H. Overkleeft, M. Dimopoulos, 2017, Scientific Reports.

Boosting autophagy in anti-tumor proteasome inhibition-mediated cardiotoxicity.

I. Trougakos, S. Gumeni, Eleni-Dimitra Papanagnou, 2023, Aging.

Cardiac mechanics in response to proteasome inhibition: a prospective study.

I. Trougakos, E. Kastritis, M. Gavriatopoulou, 2022, European heart journal. Cardiovascular Imaging.

Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent

M. Dimopoulos, I. Trougakos, O. Tsitsilonis, 2018, Oncotarget.

Implications and hidden toxicity of cardiometabolic syndrome and early‐stage heart failure in carfilzomib‐induced cardiotoxicity

P. Efentakis, M. Gavriatopoulou, E. Terpos, 2024, British journal of pharmacology.